Sugimoto T, Fujimoto D, Sato Y, Tamiya M, et al. Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis. Lung Cancer 2022;171:3-8.
PMID: 35863254